#Istat pro 4.92 download pdf
#Istat pro 4.92 download series

They were mostly women (80.52%), with a median age of 60 years (range, 18–91 years), a median disease duration of 12 years (range, 0.8–25 years), seropositive in 69.21%. From Januto December 31, 2015, the 1176 patients, who had been investigated for all the items, were enrolled in the study.

#Istat pro 4.92 download series

At the best of our knowledge, no such study has been carried out in a large Italian series and, in this study, we aimed to investigate the prevalence of both subclinical atherosclerosis and history of cardiovascular events (CVEs), in patients consecutively admitted from Januto Decemto Rheumatology Units throughout the whole Italy.Ĭenters members of GIRRCS ( Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) were invited to enrol patients consecutively admitted from Januto Decemand satisfying American College of Rheumatology/ European League Against Rheumatism criteria for RA and to investigate each of them for: traditional cardiovascular risk factors: sex, age, smoking habit, total cholesterol, triglycerides, glycaemia, high blood pressure, metabolic syndrome (MS), type 2 diabetes (T2D) RA features: disease duration as assessed from the first symptom, disease activity as evaluated by DAS28, radiographic damage as assessed by hands and feet x-ray, and previous joint surgery prevalence of both subclinical atherosclerosis and history of CVEs.Įight centers participated to the study. Several studies have pointed out a significant association between rheumatoid arthritis (RA) and accelerated atherosclerosis. Received in revised form September 4, 2017 The work cannot be changed in any way or used commercially without permission from the journal.

#Istat pro 4.92 download pdf

Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website ( This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. Supplemental digital content is available for this article. Supplemental Digital Content is available for this article. The authors report no conflicts of interest for this study. HSystemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.Ĭorrespondence: Piero Ruscitti, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, School of Medicine, University of L’Aquila, Delta 6 Building, Via dell’Ospedale, 67100, L’Aquila, Italy (e-mails:, ).Ībbreviations: ACPA = anti-citrullinated protein antibody, bDMARD = biologic disease-modifying anti-rheumatic drug, CHF = congestive heart failure, CRP = C-reactive protein, csDMARD = conventional synthetic disease-modifying anti-rheumatic drug, CV = cardiovascular, CVAs = cerebrovascular accidents, CVEs = cardiovascular events, DAS28 = disease activity score in 28 joints, GIRRCS = Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale, HBP = high blood pressure, ISTAT = Italian National Institute of Statistics, ldCCSs = low dose corticosteroids, MI = myocardial infarction, MS = metabolic syndrome, RA = rheumatoid arthritis, RF = rheumatoid factor, T2D = type 2 diabetes. ARheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’AquilaīClinical Medicine and Rheumatology Department, Campus Bio-Medico University of Rome, RomeĬRheumatology Section, Department of Internal Medicine, University of Palermo, PalermoĭRheumatology Section, Department of Clinical and Experimental Medicine, Second University of Naples, NaplesĮRheumatology Section, Department of Medical and Surgical Sciences, University of Foggia Medical School, FoggiaįDepartment of Experimental and Clinical Medicine, University of Florence, Florence